Clinical Trial Update: Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pemetrexed plus gemcitabine for treatment-resistant metastatic colorectal cancer with KRAS mutations was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Vejle Hospital | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: TERMINATED